Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 25;58(12):1595–1607. doi: 10.1007/s40262-019-00777-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

PMC Copyright notice

Fig. 6 — Dose adjustments developed with the physiologically based pharmacokinetic models for repaglinide (upper panel) and pioglitazone (lower panel). Predicted plasma concentration–time profiles are shown for European male CYP2C8 and SLCO1B1 wild-type individuals (red lines) as well as for CYP2C8*3/*3 or SLCO1B1 521CC individuals (repaglinide: green lines, pioglitazone: blue lines) before or during perpetrator drug coadministration. The left-hand plots show predicted plasma concentrations without dose adjustment; the right-hand plots show predicted plasma concentrations with dose adjustment. conc concentration, CYP cytochrome P450, n.a. not applicable, SLCO solute carrier organic anion transporter family member